The influence of long-term ingestion of D-allulose in hypercholesterolemia patients under statin therapy

Abstract

D-allulose is a non-caloric natural sugar with health benefits. A few clinical trials with continuous D-allulose intake have been reported; one indicated significant increase in low-density lipoprotein cholesterol (LDL-C) levels, though the study was not a randomized controlled trial. D-allulose is predicted to be widely used in the near future by various people; therefore, the influence of D-allulose on those who have high risk for LDL-C elevation needs to be determined. Here, the effects of D-allulose on LDL-C levels in patients with hypercholesterolemia under statin therapy were investigated in a randomized controlled trial. Twenty subjects were randomly assigned to two groups: 15 g D-allulose/day or 15 g erythritol/day (placebo); each subject consumed a daily test substance for 48 weeks. Clinical examinations were performed every eight weeks, from initial consumption until week 52. No significant increase in LDL-C was observed, although significant decrease was observed in high-density lipoprotein cholesterol (HDL-C) in the D-allulose group. HDL-C values stayed within the standard ranges during the consumption period, and the mechanism was reported to be anti-atherosclerotic. In terms of risk assessment, D-allulose did not affect all risk factors that were measured for atherosclerotic cardiovascular disease. Taken together, these results suggested that long-term D-allulose consumption did not affect LDL-C values and atherosclerotic cardiovascular disease risk in patients with hypercholesterolemia under statin therapy.

Effects of fructose epimerson blood lipid profile: A systematic review and meta-analysis of clinical trials

“…Seven trials with 593 subjects examined the fasting plasma TC outcomes (Donner et al, 2010;Ensor et al, 2015;Han et al, 2018;Hayashi et al, 2010;Tanaka et al, 2019;Tanaka et al, 2020bTanaka et al, , 2021. Compared with the placebo, the epimers of fructose increased fasting blood TC levels, but this decreased difference wasn't signi cant (Figure 4B, WMD=2.56 mg/dL; 95% CI, -2.03 to 7.14; P = 0.274).…”

“…The nal analysis consisted of 11 clinical trials, including 640 participants. Of which, eight trials studied the effect of D-allulose (Han et al, 2018;Hayashi et al, 2010;Kimura et al, 2017;Tanaka et al, 2019;Tanaka et al, 2020a;Tanaka et al, 2020bTanaka et al, , 2021Teysseire et al, 2023) and three studied D-tagatose (Buemann et al, 1998;Donner et al, 2010;Ensor et al, 2015).…”

“…Eight daily intervention trials studied the long-term effect on plasma lipid pro le, of which nine comparisons examined fasting TC, HDL-C and LDL-C, seven comparisons examined fasting TG (Buemann et al, 1998;Donner et al, 2010;Ensor et al, 2015;Han et al, 2018;Hayashi et al, 2010;Tanaka et al, 2019;Tanaka et al, 2020bTanaka et al, , 2021.…”

“…Seven trials with 593 subjects reported plasma HDL-C outcomes (Donner et al, 2010;Ensor et al, 2015;Han et al, 2018;Hayashi et al, 2010;Tanaka et al, 2019;Tanaka et al, 2020bTanaka et al, , 2021. Figure 4C shows the pooled effect of fructose epimers on fasting plasma HDL-C levels.…”